GRACE The Global Registry of Acute Coronary Events Montalescot G et al.

Slides:



Advertisements
Présentations similaires
Clinique Saint-Gatien
Advertisements

STREAM Fibrinolysis or Primary PCI in ST-segment Elevation Myocardial Infarction Armstrong P.W, et al. N Engl J Med 2013 ; 368 : Armstrong PW.
COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Boden WE et al. ACC 2007.
unstable angina undergoing PCI.
PRAGUE-8 PRAGUE-8 ESC 2007.
Prise en charge du syndrome coronarien aigu chez le patient non choqué
PLATO Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery. Held C et al. ACC 2010.
EXCELLENT The randomized comparison of 6-month vs 12-month duration of dual antiplatelet therapy after the implantation of drug eluting stent. Gwon H-C,
TAPAS Thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS) mortality and reinfarction at 1 year.
FUTURA/OASIS-8 Low versus standard dose unfractionned heparin for percutaneous coronary intervention in acute coronary syndrome patients treated with fondaparinux.
Prévention de la mortalité de l’IDM aigu
ISAR-TEST 4 Intracoronary stenting and antirestenotic results : test efficacy of 3 limus-eluting stents Mehilli J et al.
FINESSE Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events ESC 2007 FINESSE.
CLEAR PLATELETS Variabilité génétiquement déterminée de l’effet du clopidogrel Influence du polymorphism du CYP2C19 sur les effets antiplaquettaires du.
COURAGE Nuclear Differential Improvement in Stress Myocardial Perfusion Ischemia following Percutaneous Coronary Intervention as compared with Optimal.
ATOLL Acute STEMI treated with primary PCI and intravenous enoxaparin or UFH to lower ischemic and bleeding events at short and long-term follow-up. Montalescot.
ABOARD* Essai multicentrique randomisé comparant une stratégie invasive immédiate versus différée chez des patients présentant un syndrome coronarien aigu.
PEACE* Prévention par un IEC** (trandolapril) des accidents évolutifs graves chez des coronariens stables à fonction systolique ventriculaire gauche conservée.
ATLAS ACS 2 -TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome.  Présentée.
Apixaban versus warfarin in patients with atrial fibrillation
Revascularisation coronaire prophylactique avant chirurgie vasculaire
SYNTAX The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery. Primary endpoint results at one year in the randomized cohort.
CARESS-AMI Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction ESC CARESS-AMI.
RE-LY Randomization Evaluation of Long-Term Anticoagulation Therapy Connolly S.J et al. N Engl J Med 2009 ; 361.
Registre MATRIX Long term safety of DES (drug eluting stents) in off-label use : results of the MATRIX registry. Dangas G.D et al. American College of.
TRITON-TIMI 38 Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes.
ATLANTIC : ticagrelor en traitement pré-hospitalier (2)
EINSTEIN-DVT Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. Büller H et al. ESC 2010.
TRA-CER Vorapaxar, a platelet thrombin receptor antagonist, in acute coronary syndromes. Mahaffey KW et al . AHA 2011.
ISAR REACT 3A A trial of reduced dose of unfractioned heparin in biomarker negative patients undergoing percutaneous coronary intervention. Schulz S et.
Étude randomisée multicentrique
TRIANA Tratamiento del infarto agudo de miocardio en ancianos Bueno H et al.
Platelet inhibition with cangrelor in patients undergoing PCI.
PRODIGY Prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study Valgimigli M et al. ESC 2011.
Mass-DAC Drug-Eluting and Bare Metal Stenting in Diabetes Mellitus : Results from the Mass-DAC Registry. Mauri L et al. AHA 2008.
TRITON-TIMI 38 Evaluation of Prasugrel Compared with Clopidogrel in Patients with Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention:
Étude TOTAL : thrombo-aspiration lors de l’angioplastie primaire (2)
PRAGUE 7 Primary angioplasty in patients from general hospital transported to cathlab units with/without emergency thrombolysis Widimski P et al.
EARLY-ACS Inhibition de la glycoprotéine IIb/IIIa dans le syndrome coronarien aigu sans sus-décalage de ST Newby K et al. ACC Anti-GPIIb/IIIa précoce.
EXTRACT-TIMI 25 Enoxaparin and Thrombolysis reperfusion for acute myocardial infarction treatment ESC 2007 EXTRACT-TIMI 25.
Intravenous platelet blockade with cangrelor during PCI.
NORDISTEMI Norwegian study on district treatment of ST-elevation myocardial infarction Halvorsen S. et al.
TRITON-TIMI 38 Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infraction.
AVERROES Apixaban versus acetylsalicylic acid (ASA) to reduce the risk of stroke Connolly S et al. ESC 2010.
Revascularisation coronaire : ATL-endoprothèses ou chirurgie ?
AIDA STEMI The abciximab intracoronary versus intravenously drug application in ST-elevation myocardial infarction (AIDA STEMI). Thiele H et al. AHA 2011.
ISAR-REACT 4 The abciximab intracoronary versus intravenously drug application in ST-elevation myocardial infarction (AIDA STEMI). Kastrati A et al. AHA.
ICTUS Comparaison entre revascularisation coronaire précoce
OASIS-5 Comparaison du fondaparinux à l’énoxaparine dans le syndrome coronarien aigu Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Prasugrel vs Clopidogrel for Patients managed with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography : a secondary,
RE-COVER Dabigatran versus warfarine dans le traitement d’un accident thrombo-embolique veineux Schulman S et al. N Engl J Med 2009 ;361: Dabigatran.
Dr. A .BOUZERDA 1CMC .Agadir
CHARISMA Analyse post-hoc Complications hémorragiques de l’association clopidogrel + aspirine chez les patients avec maladie vasculaire stable ou avec.
EST-CE QUE LA STENOSE DE L’ARTERE CORONAIRE DROITE AUGMENTE LA MORBI- MORTALITE CHEZ LES PATIENTS CANDIDATS A UNE REVASCULARISATION MYOCARDIQUE CHIRURGICALE.
LODOCO Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease Nidorf M et al. AHA 2012.
FREEDOM Strategies for Multivessel Revascularization in Patients with Diabetes N Engl J Med 2012 DOI : /NEJMoa Farkouh ME et al. AHA 2012.
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS TIMI 51 ATLAS ACS 2 –TIMI 51 * Gibson CM.
RE-LY Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial.
FAME 2 Fractional Flow Reserve-Guided PCI versus Medical Therapy in Stable Coronary Disease De Bruyne B et al. ESC 2012.
CHARISMA Clopidogrel + aspirine contre aspirine seule pour la prévention des accidents athérothrombotiques. Bhatt DL et al. N Engl J Med 2006;354:
POISE-2 Aspirin in patients undergoing noncardiac surgery ACC Devereaux P.J, et al. N Engl J Med 2014 ; 370 :
Recombinant Administration of Ticagrelor in the cath lab or in the ambulance for new ST elevation myocardial infarction to open the coronary artery ATLANTIC.
Prasugrel vs Clopidogrel for Acute Coronary Syndromes without Revascularization TRILOGY ACS Roe MT et al. N Engl J Med 2012 ; 367:
ATLAS ACS 2 – TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome Gibson CM.
1–Thrombolysis in myocardial infarction
ATLANTIC Administration of Ticagrelor in the cath lab or in the ambulance for new ST elevation myocardial infarction to open the coronary artery Montalescot.
ACCOAST Pretreatment with prasugrel in non-ST elevation acute coronary syndromes ESC 2013 Montalescot G, et al. N Engl J Med 2013.
Platelet inhibition and patient outcomes
Strategies for Multivessel Revascularization in Patients with Diabetes
TRILOGY ACS Prasugrel vs Clopidogrel for Acute Coronary Syndromes Patients managed without Revascularization. Ohman M, et al. ESC 2012.
Transcription de la présentation:

GRACE The Global Registry of Acute Coronary Events Montalescot G et al

NOM Objectif Dans le registre international* des SCA entre (n = 43018) : établir les modalités de traitement et le pronostic du SCA sur tronc coronaire gauche (TCG) serré, non protégé (n = 2783) Critères d’inclusion SCA ST+ ou ST-, choc cardiogénique et/ou arrêt cardiocirculatoire sur TCG non protégé Méthodologie GRACE ATL=angioplastie transluminale SCA = syndrome coronaire aigu * Global Registry of Acute Coronary Events : 106 hôpitaux, 14 pays (Am. Nord et Sud, Europe, Australie, N elle Zélande) Montalescot G et al

NOM Schéma de l’étude Critère de jugement principal Mortalité intrahospitalière et à 6 mois (ajustée au score de GRACE) R PAC (n = 612) ATL=angioplastie transluminale PAC = pontage aortocoronaire * Patients exclus (n = 984/2783) : PAC (n = 921), PAC + ATL (n = 43), données manquantes (n = 20) Tt médical conventionnel seul (n = 673) SCA ST+ ou ST-, choc cardiogénique et/ou arrêt cardiocirculatoire sur TCG non protégé (n=1799, 4%)* ATL (n = (514) Montalescot G et al GRACE

NOM Résultats Score médian GRACE ATL seulePAC seul  Sévérité des SCA dans chaque groupe revascularisation au cours du temps SCA = syndrome coronaire aigu ATL=angioplastie transluminale PAC = pontage aortocoronaire ACC = arrêt cardiocirculatoire Montalescot G et al GRACE ACC ou choc cardio.SCA ST +Totalité Mortalité intra-H.34 %11 %7,7 %

NOM Résultats %  Modalités de revascularisation au cours du temps ATL seulePAC seul p < 0,001 test Mantel-Haerszel ATL=angioplastie transluminale PAC = pontage aortocoronaire Montalescot G et al GRACE

NOM Résultats Jours après admission 0 0,1 0,2 Mortalité totale ATL Médical PAC  Taux cumulés de mortalité selon les modalités de traitement ATL=angioplastie transluminale PAC = pontage aortocoronaire SCA = syndrome coronaire aigu Montalescot G et al GRACE

NOM Résultats ,04 0,08 PAC ATL Médical  Taux cumulés d’accidents vasculaires cérébraux (AVC) selon les modalités de traitement AVC Jours après admission ATL=angioplastie transluminale PAC = pontage aortocoronaire Montalescot G et al GRACE

NOM Conclusion SCA sur sténose TCG = rare (4%), grave (mortalité intra-hospitalière : 7,7%) ATL = traitement de revascularisation de 1 ère intention surtout dans situations critiques PAC améliore la survie mais dans une population à risque plus faible ATL et PAC se révèlent complémentaires SCA = syndropme coronaire aigu TCG = tronc coronaire gauche ATL=angioplastie transluminale PAC = pontage aortocoronaire Montalescot G et al GRACE